Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Bladder Cancer

  Free Subscription


1 Aging (Albany NY)
1 Ann Diagn Pathol
1 Ann Surg Oncol
1 Anticancer Agents Med Chem
1 Anticancer Drugs
2 Arch Esp Urol
1 BJU Int
2 BJUI Compass
1 BMC Surg
1 Cancer Invest
1 Cancer Med
1 Cell Commun Signal
1 Cell Rep Med
1 Chem Res Toxicol
1 Clin Genitourin Cancer
2 Curr Oncol
1 Curr Oncol Rep
1 Curr Treat Options Oncol
1 Discov Oncol
1 Environ Res
1 Eur J Clin Pharmacol
1 Eur Radiol
1 Eur Urol
1 Expert Opin Pharmacother
1 Int Braz J Urol
2 Int J Biol Sci
1 Int J Clin Oncol
1 Int J Surg
1 iScience
3 J Cancer
1 J Cancer Res Clin Oncol
2 J Cancer Res Ther
1 J Exp Clin Cancer Res
1 J Expo Sci Environ Epidemiol
1 J Med Case Rep
1 J Pers Med
1 J Pharm Biomed Anal
1 Med Oncol
1 Medicine (Baltimore)
1 Mol Biotechnol
1 Mol Imaging Radionucl Ther
1 Nat Rev Urol
1 Panminerva Med
1 Phytomedicine
1 Support Care Cancer
1 Surg Oncol
1 Toxicol Pathol
1 Urol Case Rep
1 Urol Oncol
2 Urol Pract
1 Urologia

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Aging (Albany NY)

  1. DONG Y, Wu X, Xu C, Hameed Y, et al
    Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
    Aging (Albany NY). 2024;16:2591-2616.
    PubMed         Abstract available

    Ann Diagn Pathol

  2. PALIOGIANNIS P, Lobrano R, Bella MA, Fara A, et al
    PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Ann Diagn Pathol. 2024;69:152267.
    PubMed         Abstract available

    Ann Surg Oncol

  3. OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
    Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2024 Feb 20. doi: 10.1245/s10434-024-15009.
    PubMed         Abstract available

    Anticancer Agents Med Chem

  4. FAN N, Zhang L, Wang Z, Ding H, et al
    Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.
    Anticancer Agents Med Chem. 2024;24:348-357.
    PubMed         Abstract available

    Anticancer Drugs

  5. WANG X, Song D, Zhu B, Jin Y, et al
    Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer.
    Anticancer Drugs. 2024 Feb 23. doi: 10.1097/CAD.0000000000001571.
    PubMed         Abstract available

    Arch Esp Urol

  6. LIN R, Fu X, Huang J
    Relationship between Changes of Serum Vascular Endothelial Growth Factor and Folate Receptor-alpha Levels and Clinical Efficacy of Toripalimab in Patients with Bladder Cancer.
    Arch Esp Urol. 2024;77:31-37.
    PubMed         Abstract available

  7. LI Q, Su X, Qing L, Xu W, et al
    HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer.
    Arch Esp Urol. 2024;77:79-91.
    PubMed         Abstract available

    BJU Int

  8. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
    Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
    BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
    PubMed         Abstract available

    BJUI Compass

  9. ABUHASANEIN S, Jahnson S, Kjolhede H
    Shortened time to diagnosis for patients suspected of urinary bladder cancer managed in a standardized care pathway was associated with an improvement in tumour characteristics.
    BJUI Compass. 2023;5:261-268.
    PubMed         Abstract available

  10. MIYAKE M, Kitamura H, Nishimura N, Miyamoto T, et al
    Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
    BJUI Compass. 2023;5:269-280.
    PubMed         Abstract available

    BMC Surg

  11. YAO Q, Jiang H, Niu H, Hu G, et al
    Prospective learning curve analysis of en bloc resection of bladder tumor using an ex vivo porcine model.
    BMC Surg. 2024;24:65.
    PubMed         Abstract available

    Cancer Invest

  12. XU H, Sun D, Zhou D, Sun S, et al
    Immune Cell Infiltration Types as Biomarkers for the Recurrence Diagnosis and Prognosis of Bladder Cancer.
    Cancer Invest. 2024 Feb 23:1-13. doi: 10.1080/07357907.2024.2308161.
    PubMed         Abstract available

    Cancer Med

  13. KANG NW, Feng YH, Lin KL, Chen YC, et al
    Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
    Cancer Med. 2024;13:e6972.
    PubMed         Abstract available

    Cell Commun Signal

  14. BODDU VK, Zamzow P, Kramer MW, Merseburger AS, et al
    Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.
    Cell Commun Signal. 2024;22:129.
    PubMed         Abstract available

    Cell Rep Med

  15. GALSKY MD, Guan X, Rishipathak D, Rapaport AS, et al
    Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
    Cell Rep Med. 2024;5:101393.
    PubMed         Abstract available

    Chem Res Toxicol

  16. RAGI N, Walmsley SJ, Jacobs FC, Rosenquist TA, et al
    Screening DNA Damage in the Rat Kidney and Liver by Untargeted DNA Adductomics.
    Chem Res Toxicol. 2024;37:340-360.
    PubMed         Abstract available

    Clin Genitourin Cancer

  17. YUAN H, Wang T, Peng P, Xu Z, et al
    Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment.
    Clin Genitourin Cancer. 2024 Jan 22:S1558-7673(24)00012.
    PubMed         Abstract available

    Curr Oncol

  18. TUFANO A, Rosati D, Moriconi M, Santarelli V, et al
    Diagnostic Accuracy of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Muscle-Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.
    Curr Oncol. 2024;31:818-827.
    PubMed         Abstract available

  19. LIDAGOSTER S, Ben-David R, De Leon B, Sfakianos JP, et al
    BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.
    Curr Oncol. 2024;31:1063-1078.
    PubMed         Abstract available

    Curr Oncol Rep

  20. ISALI I, Helstrom EK, Uzzo N, Lakshmanan A, et al
    Current Trends and Challenges of Microbiome Research in Bladder Cancer.
    Curr Oncol Rep. 2024 Feb 20. doi: 10.1007/s11912-024-01508.
    PubMed         Abstract available

    Curr Treat Options Oncol

  21. BERG SA, McGregor BA
    One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.
    Curr Treat Options Oncol. 2024;25:206-219.
    PubMed         Abstract available

    Discov Oncol

  22. LV H, Zhou X, Liu Y, Liu Y, et al
    Feasibility analysis of arterial CT radiomics model to predict the risk of local and metastatic recurrence after radical cystectomy for bladder cancer.
    Discov Oncol. 2024;15:40.
    PubMed         Abstract available

    Environ Res

  23. BURALLI R, Ribeiro A, Cremonese C, Vineis P, et al
    Cancer mortality and premature deaths among hairdressers in Brazil.
    Environ Res. 2024;244:117942.
    PubMed         Abstract available

    Eur J Clin Pharmacol

  24. ZHANG T, Li H, Lin C, An R, et al
    Effects of an intraoperative intravenous Bolus Dose of Dexmedetomidine on postoperative catheter-related bladder discomfort in male patients undergoing transurethral resection of bladder tumors: a randomized, double-blind, controlled trial.
    Eur J Clin Pharmacol. 2024;80:465-474.
    PubMed         Abstract available

    Eur Radiol

  25. HUANG J, Chen G, Liu H, Jiang W, et al
    MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.
    Eur Radiol. 2024;34:1804-1815.
    PubMed         Abstract available

    Eur Urol

  26. MOSCHINI M, Necchi A, Montorsi F
    Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.

    Expert Opin Pharmacother

  27. ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
    Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG).
    Expert Opin Pharmacother. 2024 Feb 23. doi: 10.1080/14656566.2024.2323609.
    PubMed         Abstract available

    Int Braz J Urol

  28. BEATRICI E, Labban M, Filipas DK, Stone BV, et al
    Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis.
    Int Braz J Urol. 2024;50:199-208.
    PubMed         Abstract available

    Int J Biol Sci

  29. YU H, Zhuang J, Zhou Z, Song Q, et al
    METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway.
    Int J Biol Sci. 2024;20:1471-1491.
    PubMed         Abstract available

  30. DU W, Tu S, Zhang W, Zhang Y, et al
    UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT.
    Int J Biol Sci. 2024;20:1389-1409.
    PubMed         Abstract available

    Int J Clin Oncol

  31. STORMOEN DR, Joensen UN, Daugaard G, Oturai P, et al
    Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice.
    Int J Clin Oncol. 2024;29:309-317.
    PubMed         Abstract available

    Int J Surg

  32. CHEN Y, Liao Y, Yang Y, Zheng X, et al
    Letter to the editor: Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Int J Surg. 2024;110:1289-1290.


  33. QI D, Lu Y, Qu H, Dong Y, et al
    Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature.
    iScience. 2024;27:109138.
    PubMed         Abstract available

    J Cancer

  34. ZHOU Q, Fang L, Tang Y, Wang Q, et al
    Exosome-mediated delivery of artificial circular RNAs for gene therapy of bladder cancer.
    J Cancer. 2024;15:1770-1778.
    PubMed         Abstract available

  35. YU L, Lin N, Ye Y, Zhou S, et al
    Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance.
    J Cancer. 2024;15:1734-1749.
    PubMed         Abstract available

  36. TAN Z, Chen X, Li H, Huang Y, et al
    HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study.
    J Cancer. 2024;15:1624-1641.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  37. HARSANYI S, Kianickova K, Katrlik J, Danisovic L, et al
    Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.
    J Cancer Res Clin Oncol. 2024;150:96.
    PubMed         Abstract available

    J Cancer Res Ther

  38. DURUR S, Uzun H, Bedir R, Nalkiran I, et al
    Prognostic importance of PD-L1 expression in bladder cancer patients.
    J Cancer Res Ther. 2023;19.
    PubMed         Abstract available

  39. SUTO H, Inui Y, Nishikawa S, Okamura A, et al
    Delayed diagnosis of bladder cancer in a patient with autosomal dominant polycystic kidney disease.
    J Cancer Res Ther. 2023;19.
    PubMed         Abstract available

    J Exp Clin Cancer Res

  40. LI T, Huang M, Sun N, Hua X, et al
    Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.
    J Exp Clin Cancer Res. 2024;43:50.
    PubMed         Abstract available

    J Expo Sci Environ Epidemiol

  41. XIE S, Friesen MC, Baris D, Schwenn M, et al
    Occupational exposure to organic solvents and risk of bladder cancer.
    J Expo Sci Environ Epidemiol. 2024 Feb 16. doi: 10.1038/s41370-024-00651.
    PubMed         Abstract available

    J Med Case Rep

  42. SAAD R, Ghaddar A, Zeenny RM
    Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
    J Med Case Rep. 2024;18:107.
    PubMed         Abstract available

    J Pers Med

  43. PROIETTI F, Flammia RS, Licari LC, Bologna E, et al
    Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience.
    J Pers Med. 2024;14:212.
    PubMed         Abstract available

    J Pharm Biomed Anal

  44. NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
    Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
    J Pharm Biomed Anal. 2024;240:115966.
    PubMed         Abstract available

    Med Oncol

  45. RAJA D, Singh A, Kurra S, Nayak B, et al
    Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
    Med Oncol. 2024;41:74.
    PubMed         Abstract available

    Medicine (Baltimore)

  46. SHAO B, Wu K, Wan S, Sun P, et al
    Prediction of future research trends in bladder urothelial carcinoma: Bibliometric analysis.
    Medicine (Baltimore). 2024;103:e37176.
    PubMed         Abstract available

    Mol Biotechnol

  47. BOTROUS S, Elmaghraby A, El-Achy S, Mustafa Y, et al
    Inhibition of TNF-alpha Oncogene Expression by Artemisia Annua L. Extract Against Pioglitazone Side Effects in Male Albino Mice.
    Mol Biotechnol. 2024;66:432-441.
    PubMed         Abstract available

    Mol Imaging Radionucl Ther

  48. ATES SG, Demirel BB, Basar H, Ucmak G, et al
    The Added-value of Staging (18)F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.
    Mol Imaging Radionucl Ther. 2024;33:11-18.
    PubMed         Abstract available

    Nat Rev Urol

  49. ZHANG S, Lin T, Xiong X, Chen C, et al
    Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence.
    Nat Rev Urol. 2024 Feb 19. doi: 10.1038/s41585-024-00857.
    PubMed         Abstract available

    Panminerva Med

  50. WANG X, Wang L
    Research progress of ICIS in the treatment of bladder cancer.
    Panminerva Med. 2024 Feb 21. doi: 10.23736/S0031-0808.24.05102.


  51. LIU S, Wang X, Sun X, Wei B, et al
    Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1.
    Phytomedicine. 2024;126:155426.
    PubMed         Abstract available

    Support Care Cancer

  52. HAN X, Gao K, Shang L, Wei L, et al
    Caregiver experiences of caring for family members with urostomy: a qualitative study.
    Support Care Cancer. 2024;32:167.
    PubMed         Abstract available

    Surg Oncol

  53. CAN O, Danis E, Kutluturk EG, Polat EC, et al
    Hybrid technique has lower stricture rates than Wallace and Bricker.
    Surg Oncol. 2024;52:102036.
    PubMed         Abstract available

    Toxicol Pathol

  54. TOSI G, Barnes JR
    Early-Onset Asymptomatic Polypoid Cystitis in Two Adolescent Male Beagle Dogs.
    Toxicol Pathol. 2023;51:357-360.
    PubMed         Abstract available

    Urol Case Rep

  55. FALABELLA R, La Falce S, Ponti FC, Di Fino G, et al
    A rare case of muscle invasive bladder cancer in a Vescical inguinal hernia.
    Urol Case Rep. 2024;53:102673.
    PubMed         Abstract available

    Urol Oncol

  56. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Shun-Fa Hung's Letter to the editor regarding the article "Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer".
    Urol Oncol. 2024 Feb 21:S1078-1439(24)00021.

    Urol Pract

  57. NAMUGOSA M, Matthew AN, Fogg R, Klausner AP, et al
    Characterization of Cystoscopy Performance and Reporting Practices at Academic Urology Centers.
    Urol Pract. 2024;11:249-253.

  58. YIP W, Assel MJ, Wong NC, Tracey AT, et al
    Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience.
    Urol Pract. 2024;11:356-366.
    PubMed         Abstract available


  59. RT R, Sharma A, Biswal D, Goel S, et al
    Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer.
    Urologia. 2024 Feb 19:3915603241232115. doi: 10.1177/03915603241232115.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.